Scarica l'app Stockscreener
68.25
0.70%
-0.48
Dopo l'orario di chiusura:
67.75
-0.50
-0.73%
Precedente Chiudi:
$68.73
Aprire:
$68.77
Volume 24 ore:
2.24M
Relative Volume:
1.51
Capitalizzazione di mercato:
$12.70B
Reddito:
$2.75B
Utile/perdita netta:
$322.29M
Rapporto P/E:
40.87
EPS:
1.67
Flusso di cassa netto:
$300.88M
1 W Prestazione:
+5.24%
1M Prestazione:
+9.15%
6M Prestazione:
-26.27%
1 anno Prestazione:
-22.92%
Intervallo 1D:
$67.76
$70.26
Intervallo di 1 settimana:
$64.35
$70.50
Portata 52W:
$60.63
$94.85
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Nome
Biomarin Pharmaceutical Inc
Settore
Industria
Telefono
(415) 506-6700
Indirizzo
105 DIGITAL DRIVE, NOVATO, CA
Confronta BMRN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
68.25 | 12.70B | 2.75B | 322.29M | 300.88M | 1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-30 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-20 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Iniziato | Evercore ISI | Outperform |
| 2023-11-15 | Iniziato | Wells Fargo | Overweight |
| 2023-10-23 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Iniziato | Raymond James | Mkt Perform |
| 2023-09-18 | Iniziato | UBS | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-07-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2023-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Iniziato | Citigroup | Neutral |
| 2023-01-30 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2022-10-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Ripresa | Wedbush | Neutral |
| 2022-04-25 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-09-09 | Aggiornamento | Stifel | Hold → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-04 | Ripresa | Guggenheim | Buy |
| 2021-03-01 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Downgrade | Stifel | Buy → Hold |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Reiterato | Citigroup | Buy |
| 2020-01-28 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-27 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-24 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-04-09 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Reiterato | Stifel | Buy |
| 2018-08-03 | Reiterato | Stifel | Buy |
Mostra tutto
Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie
BioMarin Pharmaceutical (NASDAQ:BMRN) Shares Gap Up on Strong Earnings - MarketBeat
Cantor Fitzgerald Reiterates Overweight Rating for BioMarin Pharmaceutical (NASDAQ:BMRN) - MarketBeat
UBS Group Boosts BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $113.00 - MarketBeat
Piper Sandler Raises BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $126.00 - MarketBeat
BioMarin to Report Q4 Earnings: Here's What to Expect - MSN
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $103.00 at Bank of America - MarketBeat
BioMarin Pharmaceutical Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - Simply Wall St
Zacks Research Issues Positive Estimate for BMRN Earnings - MarketBeat
Pfizer stops commercialization of hemophilia gene therapy Beqvez - Reuters
58,400 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Purchased by Alberta Investment Management Corp - MarketBeat
Cantor Fitzgerald maintains BioMarin stock with $90 target By Investing.com - Investing.com South Africa
BioMarin’s Earnings Call Highlights Strong Growth and Optimism - TipRanks
BioMarin’s Voxzogo Expected To Benefit From ‘Sticky’ Nature Of Achondroplasia Market - Scrip
Why BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher Today - Yahoo
BioMarin Pharmaceutical (NASDAQ:BMRN) Releases Quarterly Earnings Results, Beats Estimates By $0.18 EPS - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Releases FY 2025 Earnings Guidance - MarketBeat
Demystifying Biomarin Pharmaceutical: Insights From 8 Analyst Reviews - Benzinga
BioMarin Earnings: Sales Driven by Strong Uptake of Voxzogo and Enzyme Therapies; Shares Undervalued - Morningstar
BioMarin's Narrow Moat Supported by Rare Disease Therapies and Developing Pipeline - Morningstar
Cantor Fitzgerald maintains BioMarin stock with $90 target - Investing.com
UBS Adjusts Price Target on BioMarin Pharmaceutical to $113 From $109, Maintains Buy Rating - Marketscreener.com
Why Is BioMarin Stock Trading Higher On Thursday? - Benzinga
BioMarin Q4 Earnings & Sales Top Estimates, Stock Up on Upbeat '25 View - Yahoo Finance
BMO maintains $115 target on BioMarin stock, cites growth potential - Investing.com
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2024 Earnings Call Transcript - MSN
Piper Sandler lifts BioMarin stock target to $126, maintains Overweight - Investing.com
Zacks Research Analysts Boost Earnings Estimates for BMRN - MarketBeat
Roku, BioMarin, Amplitude - TradingView
BioMarin projects 10% revenue growth to $3.1B-$3.2B for 2025, driven by VOXZOGO expansion - MSN
BioMarin Pharmaceutical (BMRN) Projected to Post Quarterly Earnings on Thursday - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Purchased by New York State Teachers Retirement System - MarketBeat
BioMarin’s Record Growth and 2025 Outlook - TipRanks
After-hours movers: Carvana, Klaviyo, NerdWallet, BioMarin Pharma, and more - Investing.com
Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
BioMarin Pharmaceutical (BMRN) Surpasses Q4 Earnings and Revenue Estimates - Nasdaq
BioMarin: EPS Surges Past Expectations - The Motley Fool
BioMarin Pharma Expects Double-Digit Revenue And Profitability Growth In 2025 - Nasdaq
BioMarin: Q4 Earnings Snapshot - The Bakersfield Californian
BioMarin Pharmaceutical Q4 Non-GAAP Earnings, Revenue Rise; 2025 Outlook Set -- Shares Up After Hours - Marketscreener.com
BioMarin Pharmaceutical (NASDAQ:BMRN) Reports Bullish Q4, Stock Soars - Financial Content
BioMarin Pharmaceutical Inc. Reports Fourth Quarter and Full Year 2024 Results - TradingView
Biomarin Pharma earnings beat by $0.37, revenue topped estimates - Investing.com Canada
Earnings Flash (BMRN) Biomarin Pharmaceutical Posts Q4 Revenue $747M, vs. FactSet Est of $712.3M - Marketscreener.com
Biomarin Pharmaceutical Inc. Q4 Profit Increases, Beats Estimates - Nasdaq
BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance - PR Newswire
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Holdings Cut by Van ECK Associates Corp - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Rice Hall James & Associates LLC - MarketBeat
Rhumbline Advisers Buys 11,025 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings - The Globe and Mail
Savant Capital LLC Acquires 14,930 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast? - Yahoo Finance
Biomarin Pharmaceutical Inc Azioni (BMRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):